Emyria’s latest 4C report highlights our collaborations with leading organisations & the beginning of recruitment for our Phase 3 clinical trial of EMD-RX5 – a process that has already come to fruition with yesterday’s dosing announcement!

Read the full report at our investor hub: https://investorhub.emyria.com/